We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00400842
First Posted: November 17, 2006
Last Update Posted: July 28, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Abbott
November 16, 2006
November 17, 2006
July 28, 2011
May 2007
August 2009   (Final data collection date for primary outcome measure)
Change in CFA from baseline to the end of double-blind treatment [ Time Frame: 7 days after baseline ]
Change in Coefficient of Fat Absorption
Complete list of historical versions of study NCT00400842 on ClinicalTrials.gov Archive Site
Stool fat excretion, stool weight, stool frequency, nutritional parameters [ Time Frame: 7 days after baseline ]
Stool fat excretion, Stool weight, Stool frequency
Not Provided
Not Provided
 
A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency
A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy
This study is to verify the efficacy of 3.0 g/day of SA-001 in patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in the non-compensatory stage or by pancreatectomy as compared with placebo under a double-blind design using the change in a coefficient of fat absorption as a primary endpoint.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis
  • Drug: SA-001
    0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
  • Drug: SA-001
    0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
  • Drug: Placebo
    Placebo
  • Experimental: L
    Intervention: Drug: SA-001
  • Experimental: H
    Intervention: Drug: SA-001
  • Placebo Comparator: P
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
274
August 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Subjects with chronic pancreatitis in the non-compensatory stage or pancreatectomy
  • Subjects whose CFA is 80% or less
  • Subjects who are able to be hospitalized

Exclusion Criteria

  • Subjects who are judged to be difficult to have at least 40 g/day of fat intake during course of the study
  • Subjects who have a known allergy to porcine protein and/or any component of digestive enzyme preparations
  • Subjects who are in the acute phase of chronic pancreatitis
  • Subjects with non-pancreatic malabsorption syndrome
  • Subjects with acute pancreatitis or ileus
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00400842
S245.3.122
No
Not Provided
Not Provided
Toshiaki Yamaguchi, Sr. Clinical Program Manager, Abbott
Abbott
Not Provided
Study Director: Toshiaki Yamaguchi, BS Pharm Abbott
Abbott
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP